Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth Medicare Drug Formulary Coverage Upda…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    2026 Medicare Prescription Drug Formulary - EmblemHealth

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is EmblemHealth's 2026 Medicare formulary listing covered prescription drugs, tiers, and common plan-level restrictions (prior authorization, quantity limits, step therapy, specialty). It affects EmblemHealth Medicare prescription drug plan members, their prescribers, and pharmacies.

    Policy Summary
    PayerEmblemHealth
    Policy2026 Medicare Prescription Drug Formulary - EmblemHealth
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when a drug is marked LA or SP and ensure prescriptions comply with stated quantity limits (QL).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-04-01formulary effective/updated date
    U86Minternal formulary identifier
    Tiers 1-2drug tiering shown
    PA / QL / SP / LAcommon restrictions listed
    SPspecialty designation present

    Coverage Criteria and Formulary Rules

    inv-01: General coverage conditions

    Formulary coverage is tiered and may be subject to plan-level restrictions; coverage requires adherence to plan requirements.

    Formulary coverage conditions: Drug is listed on the formulary AND any listed restriction (PA, QL, ST, LA, SP) is satisfied per plan rules

    Providers/patients must follow authorization and quantity rules or request exceptions via member services.

    inv-02: Formulary inclusion with tiering and QL

    Coverage and utilization controls for listed outpatient drugs

    Formulary coverage: Drugs listed are included on the EmblemHealth formulary with an assigned Drug Tier; coverage subject to any stated Requirements/Limits and quantity limits (QL).

    Specific prior authorization requirements are not detailed in this excerpt; QL values provided must be observed.

    Policy Summary
    PayerEmblemHealth
    Policy2026 Medicare Prescription Drug Formulary - EmblemHealth
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization when a drug is marked LA or SP and ensure prescriptions comply with stated quantity limits (QL).
    SourceLink
    On This Page
    Coverage Criteria and Formulary RulesDrug Listings, Codes, and Quantity DesignationsPrior Authorization, Documentation, and Dispensing GuidanceExplicit Quantity Limits and ExamplesSpecialty Pharmacy, Infusion, and Site-of-Care NotesAbbreviations and Formulary FlagsStep Therapy Indicators and NotesBackground and ScopePolicy Revision History

    inv-03: Formulary listing and special handling

    Coverage and handling notes inferred from flags in list

    Formulary coverage and handling: Drugs listed include tier assignments (1 or 2) and may include requirement flags 'SP' (specialty), 'LA' (limited access), or 'QL' (quantity limit).

    Specific prior authorization criteria are not present in these chunks; presence of SP/LA/QL implies additional PBM rules.

    inv-04: Formulary coverage indicators

    Coverage varies by product; many specialty/biologic agents have utilization controls.

    Formulary coverage and controls: Drugs are listed with Drug Tier and Requirements/Limits indicators (examples: LA, SP, QL, OTC). Coverage requires adherence to those requirements; explicit medical necessity criteria not provided in this section.

    See full policy for detailed prior authorization/medical necessity criteria.

    inv-05: Formulary coverage summary

    Medications listed with Drug Tier and, where provided, Requirements/Limits (e.g., QL, SP, LA). Covered when dispensed within listed tier and quantity/program constraints.

    Formulary coverage conditions: Coverage applies according to the drug tier listed; where Requirements/Limits indicate QL, prescriptions must not exceed the stated quantity per period; where Requirements/Limits indicate SP or LA, prior authorization or specialty pharmacy enrollment is required.

    This node summarizes the operational coverage stance present in the excerpt.

    inv-06: General formulary coverage logic

    Coverage and dispensing are governed by formulary tier and requirement flags

    Formulary dispensing rules: Drug must be on formulary listing with tier assignment; if Requirements/Limits includes QL, SP, or LA, dispensing is subject to the listed limit or specialty/prior authorization processes

    Applies to each product line as listed

    inv-07: Prior authorization/Quantity limit indicators

    Coverage and utilization management indicators shown in this segment

    Formulary management indicators: Drugs marked with 'SP' or 'LA' require special program routing or prior authorization per the plan; drugs with 'QL' have explicit quantity limits; OTC indicates over-the-counter availability.

    Exact PA criteria and step edits are not specified in these chunks.

    Coverage for drugs listed in this formulary depends on the member's specific benefit plan. A listing in the guide does not guarantee payment; members and providers must consult the member's Certificate of Coverage and member ID card for plan-specific coverage, cost-sharing, and any additional requirements. Not all drugs in this list are paid for by all drug benefit plans, and prior authorization, quantity limits, specialty routing, or other plan rules may apply.

    Within the excerpted formulary pages there are no explicit product exclusions listed. Entries show drug names, tier assignments, and any Requirements/Limits fields provided; absence of an explicit exclusion in this excerpt does not imply universal coverage — refer to plan documents for exclusions that may appear elsewhere.

    No explicit exclusions are shown in these formulary fragments. The listings include tiers and Requirements/Limits flags (for example, LA or SP) for some products but do not present product-level exclusion statements in the provided excerpt.

    This segment of the formulary does not contain explicit exclusions. Product rows list the drug formulation, assigned Drug Tier, and any Requirements/Limits values; where an exclusion applies it would be documented elsewhere in plan materials.

    Some listed products are designated OTC in the Requirements/Limits field (for example, aspirin 81 mg and certain levonorgestrel formulations). OTC designation indicates the product is available without a prescription and coverage and billing rules may differ from prescription drugs; confirm benefit plan rules before billing.

    No clinical exclusion statements (medical necessity denials) are included in the provided excerpt. The entries are limited to product names, tiers, and Requirements/Limits flags; clinical coverage criteria and exclusions, if any, are maintained in other sections of the plan documentation.

    The excerpt does not show any items explicitly designated as 'not medically necessary.' Instead, entries present Drug Tier and Requirements/Limits flags (e.g., QL, SP, LA) which indicate utilization controls rather than explicit NMN determinations in this fragment.

    The provided pages do not include formal 'not medically necessary' determinations. Where utilization controls are present (e.g., LA, SP), they signal prior authorization or specialty handling may be required, but no NMN rulings are specified in this excerpt.

    No conditions or product listings in this excerpt are labeled as 'not medically necessary.' The listing format focuses on tier assignments and Requirements/Limits indicators; clinical NMN decisions are not part of the visible content here.

    Entries in this portion of the formulary primarily display Drug Tier and Requirements/Limits tags such as QL, SP, or LA. The excerpt does not include standalone clinical exclusion or 'not medically necessary' statements; instead it shows quantity limits and program flags that drive dispensing and authorization processes.

    Drug Listings, Codes, and Quantity Designations

    CARDIOVASCULAR - Calcium channel blockers / AntiarrhythmicsmixedCovered
    verapamil_hcl_cap_er_24hr_360_mgverapamil hcl cap er 24hr 360 mg (Verelan) - included
    verapamil_hcl_cap_er_24hr_120_mgverapamil hcl cap er 24hr 120 mg, 180 mg, 240 mg - included
    verapamil_hcl_tab_er_120_180_240_mgverapamil hcl tab er 120 mg, 180 mg, 240 mg - included
    verapamil_hcl_tab_40_80_120_mgverapamil hcl tab 40 mg, 80 mg, 120 mg - included
    verapamil_hcl_cap_er_100_200_300_mgverapamil hcl cap er 24hr 100 mg, 200 mg, 300 mg - noted (E formulation)
    amiodarone_hcl_tab_100_200_400_mgamiodarone hcl tab 100 mg, 200 mg, 400 mg - included
    amiodarone_hcl_inj_150mg_450mg_900mgamiodarone hcl inj 150 mg/3ml, 450 mg/9ml, 900 mg/18ml (50 mg/ml) - included
    lidocaine_iv_infusion_d5w_4mgml_8mgmllidocaine iv infusion in d5w inj 4 mg/ml, 8 mg/ml - included
    lidocaine_hcl_iv_pf_soln_100mg5ml_50mg5mllidocaine hcl (cardiac) iv pf soln 100 mg/5ml (2%), pref syr 50 mg/5ml (1%), etc. - included
    captopril_tab_12.5_25_50_100_mgcaptopril tab 12.5 mg, 25 mg, 50 mg, 100 mg - included
    1–10 of 14
    1/2
    ANTIVIRALS / Selected entriesmixedCovered
    STRIBILD_tab_150-150-200-300_mgSTRIBILD - elvitegrav-cobic-emtricitab-tenofovdf tab 150-150-200-300 mg (QL as noted)
    valacyclovir_tab_500_1000_mgvalacyclovir hcl tab 500 mg, 1 gm (Valtrex)
    tenofovir_disoproxil_tab_150_200_250_300_mgtenofovir disoproxil fumarate tab 150 mg, 200 mg, 250 mg, 300 mg (Viread)
    valganciclovir_soln_50_mg_mlvalganciclovir hcl for soln 50 mg/ml (Valcyte) and tab 450 mg
    ANTIMALARIALS / AntiparasiticsmixedCovered
    hydroxychloroquine_tab_100_200_300_400_mghydroxychloroquine sulfate tab 100 mg, 200 mg, 300 mg, 400 mg (Plaquenil)
    chloroquine_tab_250_500_mgchloroquine phosphate tab 250 mg; tab 500 mg
    atovaquone-proguanil_tab_Malaroneatovaquone-proguanil hcl tab (Malarone)
    primaquine_tab_26.3_mgprimaquine phosphate tab 26.3 mg (15 mg base)
    ANTI-INFECTIVE - MiscellaneousmixedCovered
    clindamycin_caps_75_150_300_mgclindamycin hcl cap 75 mg, 150 mg, 300 mg (Cleocin)
    linezolid_tab_600mg_susplinezolid tab 600 mg; suspension 100 mg/5ml (Zyvox)
    vancomycin_oral_iv_entriesvancomycin hcl cap 125 mg, 250 mg; iv soln 500 mg, 1 gm, 5 gm, 10 gm; oral soln 25 mg/ml, 50 mg/ml (Vancocin, Firvanq)
    sulfamethoxazole-trimethoprim_tab_iv_suspsulfamethoxazole-trimethoprim tab 400-80 mg, ds 800-160 mg; iv soln and susp forms
    SPECIFIC ANTIBACTERIAL AGENTSmixedCovered
    amoxicillin_tabs_caps_susp_strengthsamoxicillin (trihydrate) chew tabs 125 mg, 250 mg; caps 250 mg, 500 mg; tabs 500 mg, 875 mg; suspensions 125/5ml, 200/5ml, 250/5ml, 400/5ml
    amoxicillin_k_clavulanate_tabs_susp_eramoxicillin & k clavulanate susp and tabs including ES-600 and ER 12hr 1000-62.5 mg and standard strengths 250-125, 500-125, 875-125 mg
    ampicillin_entriesampicillin cap 500 mg; sodium for inj/iv soln various strengths
    VACCINES / PASSIVE IMMUNIZING / BIOLOGICALS / SELECTED SPECIALTYmixedCovered
    vaccine_list_excerptsExtensive vaccine and passive immunizing agent list (e.g., ABRYSVO, AREXVY, GARDASIL9, PNEUMOVAX 23, PREVNAR 20, SHINGRIX, COVID-19 vaccines, etc.)
    BEYFORTUS_nirsevimabBEYFORTUS - nirsevimab-alip prefilled syringe 50 mg/0.5ml, 100 mg/ml (SP)
    selected_oncology_specialty_entriesSelected antineoplastics and biologics entries appear in this section (e.g., AFINITOR, ABIRATERONE, many LA/SP designations)
    FORMULARY STRENGTHS & FORMS (Excerpt)mixed
    drug_strengths_examplesFormulary includes specific strengths and forms across classes (injectable vials, pref syringes, tabs, caps, suspensions, ER/CR formulations) as listed throughout the formulary
    quantity_limit_examplesMany entries include quantity limits (QL) where noted — examples shown in antiviral, endocrine, gastrointestinal sections

    Prior Authorization, Documentation, and Dispensing Guidance

    Documentation Required

    Special-authority or specialty product flags

    Some drugs listed in this formulary may require prior authorization (PA), be designated Limited Availability (LA), or be classified as Specialty (SP) products. These flags indicate additional routing, documentation, or dispensing requirements and may affect where and how a prescription is filled.

    • Claims must match formulary entries (drug name, strength, form) — mismatches can trigger denials.
    • Prescription documentation: prescriber name, diagnosis, and treatment history may be requested with PA.
    • Quantity-limit documentation: when a QL is listed (eg, “QL (30 tablets/30 days)”) supporting clinical rationale may be required for larger quantities.
    • Documentation placeholders: when a Requirements/Limits field is blank, additional documentation may still be requested per plan rules.
    • Special program / limited-access documentation: LA or program-specific drugs often require routing through designated specialty channels or programs.
    • LA/SP authorization notes: Limited Availability (LA) and Specialty (SP) flags commonly indicate prior authorization and/or specialty pharmacy dispensing.
    • Documentation for restricted products: many LA/SP agents (especially injectable or infused biologics and oncology agents) require clinical notes, prior therapy history, and dosing schedule.
    Prior Authorization

    Prior Authorization Required

    Prior authorization or other approval is required for many Specialty (SP) and Limited Availability (LA) products, and for select biologic and specialty agents. Authorization flags in the formulary indicate that a PA may be required to avoid denial.

    • Prior Authorization Required: PA is often required for SP/LA products — examples in the formulary include many oncology, biologic, and infusion/injectable therapies.
    • Prior authorization may be required for QL or specialty-tier drugs: exceeding a listed QL or selecting a specialty-tier alternative can trigger PA.
    • Authorization flags indicate potential denial risk: when a drug record shows LA or SP (or PA), claims submitted without prior approval are at risk of denial.
    Prior Authorization

    Specialty/Authorization requirement

    Many oncology agents and other high-cost specialty therapies are marked LA and/or SP and are routed through specialty pharmacy channels or require limited‑access routing. Prescribers should expect utilization management at point of dispensing.

    • LA or SP required for many oncology agents: formulary entries for agents such as AFINITOR, ALECENSA, AYVAKIT, and multiple chemotherapy/intravenous agents list LA, SP.
    • Specialty/limited access routing: drugs marked LA or SP may need to be dispensed by a designated specialty pharmacy or through an infusion clinic contracted with the plan.
    • LA/SP utilization management: prior authorization, step requirements, site-of-care restrictions, and mandated specialty pharmacy use are examples of utilization controls applied to these agents.
    Note

    Prior authorization may be required

    Prior authorization decisions and specialty pharmacy requirements vary by drug and by plan. The formulary does not list every possible PA condition; absence of explicit PA text in a drug row does not guarantee PA will not be required.

    • Prior authorization may be required: absence of a PA label in a single entry does not mean the product is exempt from PA under other program rules.
    • Prior authorization not enumerated in this segment: many entries show only LA/SP/QL flags — check the plan’s PA criteria for details.
    • Denial triggers not specified here: this section highlights risk areas but is not an exhaustive list of denial triggers; consult PA policies and the Certificate of Coverage.
    Prior Authorization

    Prior authorization / specialty pharmacy

    Specialty pharmacy, limited-access routing, and prior authorization flags are common drivers of claim routing and potential denials. Providers should follow plan instructions for submitting PA requests and documentation.

    • Prior authorization / specialty pharmacy: many SP drugs (eg, injectables, biologics) require dispensing via a specialty pharmacy and an approved PA prior to fill.
    • Specialty / Limited Access and Quantity Limit Denials: submitting claims that exceed QLs or that do not include required PA/authorization for LA/SP drugs may be denied.
    • Quantity limit enforcement: QLs shown (for example QL (30 tablets/30 days), QL (60 tablets/30 days), QL (360 capsules/30 days)) are actively enforced; exceeding these can prompt PA requests or claim denial.
    Step Therapy

    Step/Program indicators

    Step therapy and step/program indicators are used in some cases but are not detailed for every drug in this segment. Where step therapy applies, it will be noted as ST or described in the plan’s PA criteria.

    • Step/quantity considerations: some products are subject to both step therapy and QLs; providers should review plan criteria before prescribing.
    • Step/site-of-care noted but details absent: the formulary may flag site-of-care or step requirements without full operational detail — consult the PA policy.
    • Step therapy not detailed: if a drug is subject to ST, specific step requirements and allowable alternatives are maintained in the plan’s PA guidelines.
    Denial Risk

    Requirements/Limits and denial risk

    Follow the Requirements/Limits tags in each formulary row. When a Requirements/Limits field shows LA, SP, QL, or PA, be prepared to supply supporting clinical documentation and to use designated dispensing channels when required.

    • Requirements/Limits may trigger denial: claims that do not comply with the listed Requirements/Limits (LA, SP, QL, PA) are at risk of denial.
    • Limited access / specialty flag may trigger prior authorization: LA and SP entries commonly trigger PA workflows.
    • Authorization flags indicate potential denial risk: an LA or SP marker is a signal to initiate PA before dispensing.

    Explicit Quantity Limits and Examples

    inv-152: abacavir sulfate soln 20 mg/ml — 960 mls
    Productabacavir sulfate solution 20 mg/mL
    Quantity limit960 mL per 30 days
    TierDrug Tier = 1
    inv-153: Many antiretroviral combination tablets — 30 tablets
    Product examplesAntiretroviral combination tablets (e.g., BIKTARVY, STRIBILD, GENVOYA, DESCOVY)
    Quantity limit30 tablets per 30 days (per listed product)
    Typical tierDrug Tier = 2 for many combination products
    inv-154: ritonavir (Norvir) — 360 tablets
    Productritonavir (Norvir) 100 mg tablets
    Quantity limit360 tablets per 30 days
    TierDrug Tier = 1
    inv-155: emtriva soln — 680 mls
    ProductEMTRIVA (emtricitabine) oral solution 10 mg/mL
    Quantity limit680 mL per 28 days
    TierDrug Tier = 2
    inv-156: oseltamivir — 40 capsules
    Productoseltamivir phosphate capsules (Tamiflu)
    Quantity limit40 capsules per 120 days
    TierDrug Tier = 1
    inv-157: oseltamivir suspension — 300 mls
    Productoseltamivir phosphate suspension (Tamiflu) 6 mg/mL
    Quantity limit300 mL per 120 days
    TierDrug Tier = 1
    inv-158: zidovudine syrup — 1920 mls
    Productzidovudine syrup (Retrovir) 10 mg/mL
    Quantity limit1920 mL per 30 days
    TierDrug Tier = 1
    inv-159: STRIBILD — 30
    ProductSTRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir) tablets
    Quantity limit30 tablets per 30 days
    TierDrug Tier = 2
    inv-160: VIREAD — 30
    ProductVIREAD (tenofovir disoproxil fumarate) 300 mg tablets
    Quantity limit30 tablets per 30 days
    TierDrug Tier = 1
    inv-161: zidovudine syrup (Retrovir) — 1920
    Productzidovudine syrup (Retrovir) 10 mg/mL
    Quantity limit1920 mL per 30 days
    TierDrug Tier = 1
    inv-162: zidovudine capsules (Retrovir) — 180
    Productzidovudine capsules (Retrovir) 100 mg
    Quantity limit180 capsules per 30 days
    TierDrug Tier = 1
    inv-163: nitazoxanide — 12
    Productnitazoxanide tablets
    Quantity limit12 tablets per 90 days
    TierDrug Tier indicated in listing
    inv-164: CLIMARA PRO - estradiol-levonorgestrel td patch — 4
    ProductCLIMARA PRO (estradiol-levonorgestrel) transdermal patch
    Quantity limit4 patches per 28 days
    TierDrug Tier = 2
    inv-165: Divigel estradiol td gel packets — 30
    ProductDivigel estradiol topical gel packets
    Quantity limit30 packets per 30 days
    TierDrug Tier = 1
    inv-166: Divigel estradiol td gel (37.5 g) — 37.5
    ProductDivigel estradiol topical gel (37.5 g) bottle/packet
    Quantity limit37.5 grams per 30 days
    TierDrug Tier = 1
    inv-167: COMBIPATCH — 8
    ProductCOMBIPATCH (estradiol-norethindrone) transdermal patch
    Quantity limit8 patches per 28 days
    TierDrug Tier = 2
    inv-168: FARXIGA (dapagliflozin) — 30
    ProductFARXIGA (dapagliflozin)
    Quantity limit30 tablets per 30 days
    TierDrug Tier = 2
    inv-169: JANUVIA (sitagliptin) — 30
    ProductJANUVIA (sitagliptin)
    Quantity limit30 tablets per 30 days
    TierDrug Tier = 2
    inv-170: TRULICITY (dulaglutide) — 33
    ProductTRULICITY (dulaglutide) auto-injector pens
    Quantity limit33 pens per 30 days
    TierDrug Tier = 2
    inv-171: FIASP (insulin aspart) — 10
    ProductFIASP (insulin aspart) vials
    Quantity limit10 vials per 30 days
    TierDrug Tier = 2
    inv-172: FIASP FLEXTOUCH — 33
    ProductFIASP FLEXTOUCH (insulin aspart) pen devices
    Quantity limit33 pens per 30 days
    TierDrug Tier = 2
    inv-173: NOVOLOG MIX 70/30 — 10
    ProductNOVOLOG MIX 70/30 vials
    Quantity limit10 vials per 30 days
    TierDrug Tier = 2
    inv-174: NOVOLOG MIX 70/30 PREFILL — 33
    ProductNOVOLOG MIX 70/30 Prefill (pens)
    Quantity limit33 pens per 30 days
    TierDrug Tier = 2
    inv-175: XULTOPHY 100/3.6 — 5
    ProductXULTOPHY 100/3.6 (insulin degludec/liraglutide) pens
    Quantity limit5 pens per 30 days
    TierDrug Tier = 2
    inv-176: Combination SGLT2/Metformin and others — 30 or 60
    ProductCombination SGLT2/Metformin products (e.g., INVOKAMET, SYNJARDY, TRIJARDY XR, XIGDUO XR)
    Quantity limit30 or 60 tablets per 30 days depending on formulation
    TierDrug Tier = 2 (varies by product)
    inv-177: tolvaptan (Samsca) — 15 mg: 30 tablets/365 days; 30 mg: 60 tablets/365 days
    Producttolvaptan (Samsca)
    Quantity limits15 mg: 30 tablets per 365 days; 30 mg: 60 tablets per 365 days
    TierDrug Tier = 1; Requirements/Limits = QL and SP
    inv-178: ADVAIR HFA / various inhalers — examples include 1 inhaler/30 days, 2 inhalers/30 days, 60 blisters/30 days
    Product examplesADVAIR HFA and various inhaler controllers
    Quantity limitsExamples include 1 inhaler/30 days, 2 inhalers/30 days, or 60 blisters/30 days depending on product
    TierDrug Tier = 2 for many inhaled controllers
    inv-179: SPIRIVA HANDIHALER — 30 capsules/30 days
    ProductSPIRIVA HANDIHALER (tiotropium capsules)
    Quantity limit30 capsules per 30 days
    TierDrug Tier = 1
    inv-180: dexlansoprazole 30 mg — 60 capsules
    Productdexlansoprazole 30 mg (Dexilant)
    Quantity limit60 capsules per 30 days
    TierDrug Tier = 1
    inv-181: lanthanum carbonate chewable — 270 tablets
    Productlanthanum carbonate chewable (Fosrenol)
    Quantity limit270 tablets per 30 days
    TierDrug Tier = 1
    inv-182: sevelamer carbonate packet — 510 packets
    Productsevelamer carbonate packets (Renvela)
    Quantity limit510 packets per 30 days
    TierDrug Tier = 1
    inv-183: oxybutynin chloride solution — 600 mL
    Productoxybutynin chloride solution 5 mg/5 mL
    Quantity limit600 mL per 30 days
    TierDrug Tier = 1
    inv-184: MYRBETRIQ - mirabegron ER — 30 tablets
    ProductMYRBETRIQ (mirabegron) ER tablets
    Quantity limit30 tablets per 30 days
    TierDrug Tier = 2
    inv-185: oxybutynin chloride solution — 600 mls
    Productoxybutynin chloride solution 5 mg/5 mL
    Quantity limit600 mL per 30 days
    TierDrug Tier = 1
    inv-186: oxybutynin chloride ER 10 mg,15 mg — 60 tablets
    Productoxybutynin chloride ER 10 mg, 15 mg
    Quantity limit60 tablets per 30 days
    TierDrug Tier = 1
    inv-187: oxybutynin chloride 5 mg — 120 tablets
    Productoxybutynin chloride 5 mg tablets
    Quantity limit120 tablets per 30 days
    TierDrug Tier = 1
    inv-188: solifenacin succinate (Vesicare) — 30 tablets
    Productsolifenacin succinate (Vesicare)
    Quantity limit30 tablets per 30 days
    TierDrug Tier = 1
    inv-189: tolterodine tartrate ER — 30 capsules
    Producttolterodine tartrate ER capsules
    Quantity limit30 capsules per 30 days
    TierDrug Tier = 1
    inv-190: tolterodine tartrate tab 1 mg — 60 tablets
    Producttolterodine tartrate tablets 1 mg
    Quantity limit60 tablets per 30 days
    TierDrug Tier = 1
    inv-191: trospium chloride ER 60 mg — 30 capsules
    Producttrospium chloride ER 60 mg capsules
    Quantity limit30 capsules per 30 days
    TierDrug Tier = 1
    inv-192: trospium chloride 20 mg — 60 tablets
    Producttrospium chloride 20 mg tablets
    Quantity limit60 tablets per 30 days
    TierDrug Tier = 1
    inv-193: estradiol vaginal cream (Estrace) — 255 grams
    Productestradiol vaginal cream (Estrace)
    Quantity limit255 grams per 365 days
    TierDrug Tier indicated in listing
    inv-194: ESTRING - estradiol vaginal ring — 1 ring
    ProductESTRING (estradiol vaginal ring)
    Quantity limit1 ring per 90 days
    TierDrug Tier = 2
    inv-195: Amphetamine-dextroamphetamine examples — various QL values (180 tablets/30 days, 60 capsules/30 days, 30 capsules/30 days)
    Product classamphetamine-dextroamphetamine formulations (various strengths/brands)
    Quantity limitsExamples include 180 tablets/30 days, 60 capsules/30 days, 30 capsules/30 days depending on formulation
    TierDrug Tier varies by product (listed in entries)
    inv-196: Methylphenidate examples — QL 60 tablets/30 days, 30 capsules/30 days, 360 tablets/30 days
    Product classmethylphenidate formulations (multiple forms)
    Quantity limitsExamples include QL 60 tablets/30 days, 30 capsules/30 days, up to 360 tablets/30 days for some formulations
    TierDrug Tier varies by formulation
    inv-197: pregabalin ER (Lyrica CR) — QL 30 tablets/30 days (82.5/165 mg) and QL 60 tablets/30 days (330 mg)
    Productpregabalin ER (Lyrica CR) 82.5 mg, 165 mg, 330 mg
    Quantity limits82.5/165 mg: QL 30 tablets/30 days; 330 mg: QL 60 tablets/30 days
    TierDrug Tier = 1
    inv-198: pregabalin ER 82.5 mg, 165 mg — 30
    Product strengthspregabalin ER 82.5 mg, 165 mg
    Quantity limit30 tablets per 30 days (per listing)
    TierDrug Tier = 1
    inv-199: SAVELLA (milnacipran) tablets — 60
    ProductSAVELLA (milnacipran) tablets
    Quantity limit60 tablets per 30 days
    TierDrug Tier = 2
    inv-200: butalbital-acetaminophen — 180
    Productbutalbital-acetaminophen formulations
    Quantity limit180 capsules/tablets per 30 days
    TierDrug Tier = 1
    inv-201: buprenorphine-naloxone films/tabs — varies (60-120)
    Productbuprenorphine-naloxone films/tabs (Suboxone and others)
    Quantity limitExamples vary by formulation (QLs listed: 60–120 per 30 days)
    TierDrug Tier = 1
    inv-202: methadone and morphine oral solutions — examples 900 mls/30 days, 2700 mls/30 days
    Product classmethadone and morphine oral solutions
    Quantity limitsExamples include 900 mL/30 days and 2700 mL/30 days depending on formulation
    TierVarious tiers as listed
    inv-203: morphine sulfate oral soln 10 mg/5ml — 2700
    Productmorphine sulfate oral solution 10 mg/5 mL
    Quantity limit2700 mL per 30 days
    TierDrug Tier listed in formulary entries
    inv-204: morphine sulfate oral soln 20 mg/5ml — 1350
    Productmorphine sulfate oral solution 20 mg/5 mL
    Quantity limit1350 mL per 30 days
    TierDrug Tier listed in formulary entries
    inv-205: oxycodone w/ acetaminophen tab 7.5-300 mg — 240
    Productoxycodone w/ acetaminophen 7.5/300 mg tablets
    Quantity limit240 tablets per 30 days
    TierDrug Tier = 2
    inv-206: oxycodone soln 5 mg/5ml — 5400
    Productoxycodone oral solution 5 mg/5 mL
    Quantity limit5400 mL per 30 days
    TierDrug Tier = 1
    inv-207: oxycodone tab 5 mg — 360
    Productoxycodone tablets 5 mg
    Quantity limit360 tablets per 30 days
    TierDrug Tier = 1
    inv-208: pregabalin (various strengths) — 360; 270; 180; 90; 60 capsules per 30 days; solution 900 mL/30 days
    Product classpregabalin (various strengths) — Lyrica and formulations
    Quantity limitsExamples: 360, 270, 180, 90, 60 capsules per 30 days depending on strength; solution 900 mL/30 days
    TierDrug Tier = 1 (as listed)

    Specialty Pharmacy, Infusion, and Site-of-Care Notes

    Note

    Coordinate with infusion center or specialty pharmacy

    Some products flagged LA or SP imply limited site‑of‑care or specialty pharmacy distribution; coordinate with the specialty pharmacy or infusion center to ensure correct routing and authorization.

    Billing Rule

    Do not dispense retail when SP/LA requires specialty routing

    Certain products designated 'SP' or 'LA, SP' indicate specialty pharmacy or limited access site‑of‑care requirements; do not dispense via retail when specialty routing is required.

    Billing Rule

    Route oncology/biologics to specialty pharmacy

    Several oncology and biologic agents are designated Requirements/Limits = SP, indicating they are managed through specialty pharmacy channels and may require specialty handling and authorization.

    Note

    Verify infusion vs. specialty pharmacy site for IV biologics

    Certain IV biologics and specialty agents indicate SP and LA which implies administration in an infusion center or managed distribution through specialty pharmacy — verify site and authorization prior to administration.

    Note

    Manage SP/LA agents via specialty or limited‑access channels

    Some specialty agents are designated SP/LA and typically require management through specialty pharmacy or limited‑access channels; coordinate home infusion or clinic administration as indicated by the program.

    Billing Rule

    Use specialty pharmacy for SP/LA products

    Products flagged 'SP' or 'LA' are handled via specialty pharmacy or limited‑access channels and will require prior authorization and program enrollment before dispensing.

    Note

    Confirm administration site for injectable biologics

    Some IV/subcutaneous biologic products list Requirements/Limits = SP or LA which may route administration to infusion center, office, or specialty pharmacy; confirm site‑of‑care and authorization prior to scheduling.

    Billing Rule

    Adalimumab biosimilars require specialty program routing

    Multiple adalimumab biosimilars are listed with Requirements/Limits = SP, indicating biosimilars are managed through specialty program/prior authorization routing similar to reference products.

    Abbreviations and Formulary Flags

    Step Therapy Indicators and Notes

    Step therapy note
    Step therapy (ST) may require that a member try specified preferred or lower‑tier drugs first before a non‑preferred drug will be covered; exceptions can be requested through member services.
    Step therapy sequences
    No explicit step therapy sequences are detailed in the provided formulary excerpts; tiering and QL flags suggest utilization controls but do not define ordered steps.
    Step therapy sequences (fragment)
    The fragment lists many products with Requirements/Limits (e.g., QL, SP, LA) but does not provide explicit step‑therapy sequences or required prior agents to be tried first.
    LA flag implication
    Entries annotated with LA (Limited Availability) may indicate limited access that often accompanies prior authorization or a requirement to meet prior step conditions before coverage, although specific step rules are not listed.
    Explicit step-therapy steps listed?
    No explicit step‑therapy steps are listed in this excerpt of the formulary.
    SP/LA specialty routing requirement
    Products marked SP or LA are noted as requiring specialty pharmacy handling or limited access authorization prior to coverage, which may functionally require specialty routing before benefit approval.
    Quantity limits and step edits
    Quantity limits (QL) and tier assignments shown for inhaled controllers and other agents (examples: ADVAIR HFA QL 1 inhaler/30 days; ASMANEX HFA QL 1 canister/30 days) suggest these products may be subject to step edits or quantity‑based program controls.
    SP/LA annotations and step implication
    Specialty/LA annotations on many biologic and specialty agents (e.g., OMVOH, mirikizumab) imply these products are managed via specialty programs and may be subject to step or programmatic routing, though specific step sequences are not provided.
    Specialty pharmacy / prior authorization handling
    Some limited‑availability or specialty agents (e.g., ZYMFENTRA, NUPLAZID) are managed through specialty pharmacy channels and require prior authorization or program enrollment before coverage is provided.
    Explicit step sequences provided?
    No explicit step‑therapy sequences are provided in the excerpts reviewed; the document lists requirement flags and QL values but does not enumerate ordered step requirements.
    LA/SP designation implication
    LA or SP designations indicate limited access or specialty program management that often implies additional authorization or routing (and may be associated with step or site‑of‑care requirements), even though explicit step rules are not shown.
    SP/LA subject to step edits or PA?
    Drugs marked SP or LA are typically subject to utilization management such as prior authorization, specialty pharmacy routing, or step edits; the formulary excerpts show these flags but do not list specific step sequences.

    Background and Scope

    Background: This formulary shows both brand-name and generic products and indicates tier placement plus common utilization controls. Listings include Drug Tier assignments and a Requirements/Limits field that may show QL (quantity limit), SP (specialty program/site or specialty pharmacy), or LA (limited access). These flags denote operational controls: QLs specify maximum quantities per period, and SP/LA entries indicate specialty routing or prior authorization processes that must be satisfied for coverage.

    Policy Revision History

    2026-04-01policy_effectiveLatest

    Formulary was updated and is effective as of April 1, 2026.

    2026-04-26document_publication

    Document contains EmblemHealth contact and Formulary ID U86M with publication reference dated April 26, 2026.